期刊
ACTA PHARMACOLOGICA SINICA
卷 34, 期 1, 页码 10-16出版社
ACTA PHARMACOLOGICA SINICA
DOI: 10.1038/aps.2012.94
关键词
ion channels; TRPM7; cerebral ischemia; stroke; neuroprotection; recombinant tissue plasminogen activator (rt-PA); glutamate receptors
资金
- Natural Sciences and Engineering Research Council of Canada
- Ontario Graduate Scholarship
The initial excitement and counties efforts to find a pharmacological agent that disrupts the excitotoxic pathway of ischemic neuronal death have only led to disappointing clinical trials. Currently, a thrombolytic agent called. recombinant tissue plasminogen activator (rt-PA) is the only pharmacological treatment available for patients with acute ischemic stroke in most countries. Even though its efficacy has been confirmed repeatedly, rt-PA is considerably underused due to reasons including a short therapeutic window and repeated complications associated with its use. A search for alternative mechanisms that may operate dependently or independently with the well-established excitotoxic mechanism has led researchers to the discovery of newly described non-glutamate mechanisms. Among the latter, transient receptor potential melastatin 7 (TRPM7) is one of the important nonglutamate mechanisms in stroke, which has been evaluated in both in-vitro and in-vivo. In this review, we will discuss the current state of pharmacological treatments of ischemic stroke and provide evidence that TRPM7 is a promising therapeutic target of stroke.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据